NFL Biosciences Gains Scientific Validation with Three SRNT-Europe Presentations
Event summary
- Three NFL Biosciences presentations accepted for the 2026 SRNT-Europe Conference, including one oral presentation on NFL-102.
- Oral presentation focuses on NFL-102's effects on neuroimmune and signaling pathways in tobacco-smoke exposure mouse models.
- Two posters detail NFL-101 biomarker analysis and TONIC trial design for NFL-102.
- Conference runs September 21–23, 2026, in Paris.
The big picture
NFL Biosciences' acceptance of three presentations at the SRNT-Europe Conference underscores growing scientific validation for its addiction-treatment pipeline. The focus on neuroimmune pathways and biomarker-driven personalized medicine aligns with broader industry trends toward precision therapeutics in nicotine dependence. Success here could position NFL Biosciences as a key player in developing safer, natural alternatives to existing smoking-cessation treatments.
What we're watching
- Clinical Validation
- Whether NFL Biosciences can translate scientific recognition into clinical trial success for NFL-102.
- Biomarker Strategy
- How baseline IgG1 levels as a predictive biomarker for NFL-101 will impact patient selection and outcomes.
- Market Differentiation
- The pace at which NFL Biosciences can establish its botanical drug candidates as viable alternatives in smoking cessation.